Our studies would suggest that targeting downstream effectors of PEDF, such as VEGFR translocation and/or processing or γ-secretase activity may represent a promising therapeutic strategy for the treatment of diabetic vascular complications in the eye and other organs. This evidence concerns the gene KDR and complication.